What the opinion does and does not do.

It is worth being clear about what this opinion is and is not. It is a legal memorandum from the executive branch’s internal counsel, not a regulatory action. It does not rescind any existing regulation. It does not require states to change how they deliver care.

What it does is signal that the current administration views the integration mandate regulations at 45 C.F.R. § 84.76(b) and 28 C.F.R. § 35.130(d) as legally unsupported, and that federal enforcement of those regulations may no longer reflect administration priorities.

Whether that signal leads to formal rulemaking, reduced enforcement activity, or something else entirely remains to be seen.

We are monitoring this closely. Our comments here reflect what we know now, not predictions about outcomes that have not yet materialized.

The research ecosystem connection.

Community-based mental health systems are a significant component of the U.S. mental health research landscape. They are not the only pathway into clinical trials, and characterizing them as indispensable would overstate the case. What they do provide, in meaningful and documentable ways, is access to trusted relationships, established recruitment pathways, participant support infrastructure, and real-world patient populations that reflect the clinical complexity sponsors need in their study samples.

Those contributions developed alongside, and in some cases because of, the policy environment that the integration mandate helped shape over the past 25 years. If that environment shifts, the research implications are worth assessing honestly rather than assuming they will be negligible or catastrophic. The honest answer right now is that we do not know what the downstream effects will be. The pace of any change, the responses of individual states, and the behavior of community-based organizations themselves will all shape the outcome.

What we do know is that the research community benefits from paying attention now rather than after enrollment pipelines have already been affected.

Research access should follow the patient.

Whatever care settings look like in the years ahead, the principle that research access should follow the patient remains sound. If the distribution of care settings shifts, trial designs, site networks, and community engagement strategies will need to reflect that reality. That kind of adaptation takes time. It is better to begin the conversation during a period of uncertainty than to scramble after the fact.

What we are asking.

We are watching for any formal regulatory action, including notice-and-comment rulemaking, that would change the legal landscape. If a comment period opens, STARR will submit comment focused on the mental health clinical research implications. In the meantime, we are asking the stakeholders we work alongside to begin asking their own questions:

• Clinical research sites and community-based organizations should assess whether their current recruitment and retention strategies have meaningful dependencies on community-based care infrastructure, and what contingency planning looks like if that infrastructure contracts or shifts in their region.
• Pharmaceutical sponsors and CROs should consider whether shifts in care setting distribution among SMI populations may affect site selection, enrollment modeling, and participant retention planning for ongoing and planned mental health trials. The uncertainty created by this opinion is itself relevant information for research planning.
• Federal agencies, including the FDA and NIH, are well positioned to monitor whether changes in care delivery patterns affect the representativeness and feasibility of mental health clinical trials, and to consider that question in guidance on trial design and community engagement.
• State mental health authorities should recognize that the research relationships built alongside community-based care systems represent real value, independent of the legal questions now in play, and worth preserving where possible.